Joseph T. Jaros

Joseph T. Jaros is a Partner at Rakoczy Molino Mazzochi Siwik LLP (RMMS), where his practice primarily focuses on Hatch-Waxman litigation. With nearly two decades of complex litigation experience, he has dedicated approximately ten years exclusively to managing Hatch-Waxman matters. His expertise spans a range of pharmaceutical technologies, including new chemical entities, polymorphs, drug delivery devices, formulations, and methods of treatment. His involvement in this specialized area includes cases concerning drugs such as mometasone (Nasonex), aripiprazole (Abilify), bimatoprost (Latisse), and doxycycline (Oracea). Prior to joining RMMS, Mr. Jaros was an associate at Kirkland & Ellis LLP and Holland & Hart LLP.

Within the pharmaceutical patent landscape, Mr. Jaros's firm, RMMS, is well-regarded for its representation of generic pharmaceutical manufacturers in high-stakes patent litigation against brand-name drug owners. While the provided case list shows one plaintiff-side appearance for Stratasys, Inc. in a case involving 3D printing technology, his current firm's and his recent profile's emphasis is strongly on representing generic drug manufacturers, often acting as defendants in infringement suits or as plaintiffs in declaratory judgment actions challenging brand patents.

Mr. Jaros has been involved in significant outcomes for his firm's clients, including non-infringement victories involving generic doxycycline capsules and ZTLido® (lidocaine topical system), and successful affirmations at the Federal Circuit, such as a collateral estoppel decision concerning Latisse® (bimatoprost topical solution). While his professional profile details extensive patent litigation experience, specific mentions of his regular appearance in PTAB or IPR proceedings are not explicitly detailed.

He earned his Juris Doctor from Northwestern University School of Law in 1999 and a Bachelor of Arts from the University of Chicago in 1993, where he was Phi Beta Kappa. Mr. Jaros is admitted to practice in Illinois and Colorado, and before the Federal Circuit Court of Appeals.